Somchai Wongkhantee
Overview
Explore the profile of Somchai Wongkhantee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
35
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tirachotikul T, Rattanathammethee T, Makruasi N, Chintabanyat A, Julamanee J, Khuhapinant A, et al.
Ann Hematol
. 2024 Aug;
103(12):5741-5748.
PMID: 39177795
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare subtype of T-cell lymphomas with a characteristic feature of subcutaneous nodules associated with hemophagocytic lymphohistiocytosis (HLH). Treatment options for SPTCL are mainly...
2.
Thanhakun R, Wudhikarn K, Bunworasate U, Rattanathammethee T, Norasetthada L, Kanya P, et al.
Ann Hematol
. 2023 Sep;
102(12):3533-3541.
PMID: 37718327
Several prognostic models have been introduced to predict outcomes of patients with diffuse large B-cell lymphoma (DLBCL). Endothelial activation and stress index (EASIX) is a surrogate of endothelial dysfunction which...
3.
Rattanathammethee T, Norasetthada L, Bunworasate U, Wudhikarn K, Julamanee J, Noiperm P, et al.
Ann Hematol
. 2023 May;
102(7):1887-1895.
PMID: 37202499
Relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) is a challenging condition to treat, and there is an unmet clinical need for effective therapies. Recently, polatuzumab vedotin (Pola), an anti-CD79b antibody-drug-conjugate...
4.
Norasetthada L, Wongkhantee S, Chaipokam J, Charoenprasert K, Chuncharunee S, Rojnuckarin P, et al.
Ann Hematol
. 2021 Jul;
100(10):2443-2452.
PMID: 34269837
The incidence and outcomes of aplastic anemia (AA) in Asia remain limited. This study aimed to explore the incidence and outcomes of patients with adult AA across the country of...
5.
Wudhikarn K, Bunworasate U, Julamanee J, Lekhakula A, Ekwattanakit S, Khuhapinant A, et al.
Leuk Lymphoma
. 2020 Jun;
61(11):2614-2621.
PMID: 32573294
Event-free survival at 12 months (EFS12) is a surrogate endpoint for long-term outcomes in many histologic lymphoma subtypes. However, most reports have primarily investigated the implication of EFS12 in advanced-stage...
6.
Wudhikarn K, Bunworasate U, Julamanee J, Lekhakula A, Ekwattanakit S, Khuhapinant A, et al.
Hematol Oncol
. 2019 Nov;
37(5):578-585.
PMID: 31702065
Event free survival at 24 months (EFS24) has been described as a powerful predictor for outcome in several subtypes of B cell lymphoma. However, it was limitedly described in T...
7.
Wudhikarn K, Bunworasate U, Julamanee J, Lekhakula A, Ekwattanakit S, Khuhapinant A, et al.
J Geriatr Oncol
. 2019 Apr;
11(1):62-68.
PMID: 30940492
Introduction: Peripheral T cell NHL (PTCL) and natural killer/T cell NHL (NKTCL) are relatively rare disorders. Data on clinical presentation, treatment and outcome are limited especially in older age groups....
8.
Intragumtornchai T, Bunworasate U, Wudhikarn K, Lekhakula A, Julamanee J, Chansung K, et al.
Hematol Oncol
. 2017 Mar;
36(1):28-36.
PMID: 28332735
Systemic reports on the descriptive epidemiology of non-Hodgkin lymphoma (NHL) from Southeast Asia are scarce. A nationwide multi-institutional registry was conducted to compare the histopathology, clinical features, and survival of...
9.
Wudhikarn K, Bunworasate U, Julamanee J, Lekhakula A, Chuncharunee S, Niparuck P, et al.
Ann Hematol
. 2016 Oct;
96(1):57-64.
PMID: 27752821
Secondary central nervous system (CNS) relapse is a serious and fatal complication of diffuse large B cell lymphoma (DLBCL). Data on secondary CNS (SCNS) relapse were mostly obtained from western...
10.
Intragumtornchai T, Bunworasate U, Siritanaratkul N, Khuhapinant A, Nawarawong W, Norasetthada L, et al.
Leuk Lymphoma
. 2012 Jun;
54(1):83-9.
PMID: 22646050
The impact of health insurance with inequitable rituximab coverage on the survival of patients with diffuse large B-cell lymphoma (DLBCL) has never been reported. We conducted a nationwide multicenter analysis...